Imaging of Isocitrate Dehydrogenase-Mutant Gliomas in the Era of Isocitrate Dehydrogenase Inhibitors: What Radiologists Need to Know
Year: 2026
Type: review
Abstract: Isocitrate dehydrogenase (IDH)-mutant gliomas, including IDH-mutant astrocytomas and IDH-mutant and 1p/19q-codeleted oligodendrogliomas, exhibit biologically distinct behaviors from IDH-wildtype glioblastomas, showing better survival outcomes and requiring different treatment strategies. The recent FDA approval of vorasidenib, an IDH mutation inhibitor, has introduced a paradigm shift in the treatment of IDH-mutant gliomas and has focused attention to the role of imaging information in the routine clinical management of these tumors. In this review, we provide an overview of the clinical fundamentals of IDH-mutant gliomas and highlight the preoperative and postoperative imaging features of these lesions, which are important for radiologists to recognize and communicate with clinicians.
Source: Korean Journal of Radiology
Institutions: Asan Medical Center, University of Ulsan, Technical University of Munich, German Cancer Research Center, University Hospital Bonn, University Hospital Heidelberg, Deutsches Konsortium für Translationale Krebsforschung, Yonsei University, Yonsei University Health System, Johns Hopkins University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7223669668